<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01941576</url>
  </required_header>
  <id_info>
    <org_study_id>SJTUMS-20130903</org_study_id>
    <nct_id>NCT01941576</nct_id>
  </id_info>
  <brief_title>Effects of rhBNP in Pediatrics After Corrective Repair of Tetralogy Of Fallot</brief_title>
  <official_title>Effects of rhBNP in Pediatrics After Corrective Repair of Tetralogy Of Fallot</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of rhRNP on urine output and
      hemodynamics following corrective repair of Tetralogy Of Fallot.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CVP(central venous pressure) and cardiac output are serious index in children with Tetralogy
      Of Fallot after the corrective repair.The purpose of this study is to investigate if the
      therapy of rhRNP can improve the survival and life quality after the corrective repair of
      Tetralogy Of Fallot.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2013</start_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from Baseline in BNP and CVP after the infusion of rhBNP</measure>
    <time_frame>12 months after operation of Tetralogy Of Fallot</time_frame>
    <description>we will evaluate the cardiac function through the consecutive changed numerical value of brain natriuretic peptide and Central Venous Pressure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline on the volume of urine out and numerical value of serum creatinine and blood urea nitrogen</measure>
    <time_frame>12 months after operation of Tetralogy Of Fallot</time_frame>
    <description>we evaluate the renal function through the volume of urine out and numerical value of serum creatinine and blood urea nitrogen.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Congenital Heart Defects</condition>
  <condition>Tetralogy Of Fallot</condition>
  <arm_group>
    <arm_group_label>rhBNP Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients after corrective repair of Tetralogy Of Fallot will be treat with routinely therapy, including inotropics and diuretics, combined a rhBNP infusion 24 hours after operation. The dose of recombinant human brain natriuretic peptide (rhBNP) will be 1.5 mcg/kg for loading, followed by continuous infusion recombinant human brain natriuretic peptide 0.01-0.01mcg/kg/min for 72 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients after corrective repair of Tetralogy Of Fallot will be treat with routinely therapy, including inotropics and diuretics, combined a placebo infusion 24 hours after operation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant human brain natriuretic peptide (rhBNP)</intervention_name>
    <description>Patients are first given a loading dose of recombinant human brain natriuretic peptide (rhBNP) 1.5 mcg/kg, followed by continuous infusion recombinant human brain natriuretic peptide 0.01-0.01mcg/kg/min for 72 hours.</description>
    <arm_group_label>rhBNP Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (0.9% sodium chloride)</intervention_name>
    <description>Patients after corrective repair of Tetralogy Of Fallot will be treat with routinely therapy, including inotropics and diuretics, combined a placebo infusion 24 hours after operation.</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent obtained from patient's legally acceptable representative.

          -  Pediatric patients after Repair of Tetralogy Of Fallot.

        Exclusion Criteria:

          -  Psychotic, addictive or other disorder limiting the ability to provide informed
             consent or to comply with study requirements.

          -  Treatment or planned treatment with another investigational drug within 3 months of
             screening.

          -  Known hypersensitivity to bosentan or any of the excipients

          -  cardiogenic shock and inclination of hypotension（SBP&lt; 60mmHg）.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhuoming Xu, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Cardiac intensive care unit, Department of cardiothoracic vascular surgery, Shanghai Children's Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiac intensive care unit, Department of cardiothoracic vascular surgery, Shanghai Children's Medical Center, Medical college of Shanghai Jiaotong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhuoming Xu, MD PhD</last_name>
      <phone>86213501699158</phone>
      <email>zmxyfb@aliyun.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2013</study_first_submitted>
  <study_first_submitted_qc>September 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2013</study_first_posted>
  <last_update_submitted>April 20, 2016</last_update_submitted>
  <last_update_submitted_qc>April 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Xu Zhuoming</investigator_full_name>
    <investigator_title>Vice Chief, Department of thoracic and cardiovascular surgery</investigator_title>
  </responsible_party>
  <keyword>Heart defects, Congenital</keyword>
  <keyword>rhBNP</keyword>
  <keyword>heart failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Defects, Congenital</mesh_term>
    <mesh_term>Tetralogy of Fallot</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diuretics</mesh_term>
    <mesh_term>Natriuretic Peptide, Brain</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

